Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(46): 5288-5296 [PMID: 30581277 DOI: 10.3748/wjg.v24.i46.5288]